-
New data show durable response following treatment with ADSTILADRIN® (nadofaragene firadenovec-vncg)
in PRESS RELEASE 2023 on…
-
-
Royalty Pharma and Ferring Pharmaceuticals enter into US $500 million royalty agreement for new intravesical gene therapy Adstiladrin® (nadofaragene firadenovec-vncg)
in PRESS RELEASE 2023 on -
Ferring Pharmaceuticals appoints new Executive Chairman among key changes to Board of Directors
in PRESS RELEASE 2023 onAd hoc announcement pursuant to Art. 53 LR Ferring Pharmaceuticals appoints new…
PRESS RELEASE 2023
PRESS RELEASE 2023